Lau, G K K <br/><br/>
Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.  [electronic resource] 

 -  Journal of viral hepatitis  Jul 2002 
 - 280-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1352-0504 
<br/><br/><label>Standard No.: </label>10.1046/j.1365-2893.2002.00361.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Aminopurine--analogs & derivatives<br/>Adjuvants, Immunologic--therapeutic use<br/>Adolescent<br/>Adult<br/>Antiviral Agents--therapeutic use<br/>Cell Division<br/>Cells, Cultured<br/>Cytokines--biosynthesis<br/>DNA, Viral--blood<br/>Drug Therapy, Combination<br/>Famciclovir<br/>Female<br/>Hepatitis B Core Antigens--immunology<br/>Hepatitis B Surface Antigens--immunology<br/>Hepatitis B e Antigens--blood<br/>Hepatitis B virus--genetics<br/>Hepatitis B, Chronic--blood<br/>Humans<br/>Immune Tolerance<br/>Male<br/>Middle Aged<br/>T-Lymphocytes--drug effects<br/>Thymalfasin<br/>Thymosin--analogs & derivatives<br/>Time Factors